Data_Sheet_1_Matrix Metallopeptidase 14: A Candidate Prognostic Biomarker for Diffuse Large B-Cell Lymphoma.docx

BackgroundMatrix metallopeptidase 14 (MMP14) is an important gene in the regulation of T-cell function. However, the correlation between MMP14 expression, prognosis, and immune cell infiltration in diffuse large B-cell lymphoma (DLBCL) remains unclear.MethodsWe investigated the influence of MMP14 on clinical prognosis using data obtained from three Gene Expression Omnibus (GEO) database sets (GSE98588, GSE10846, and GSE4475). The expression of MMP14 was analyzed using the Gene Expression Profiling Interactive Analysis (GEPIA). The correlation between MMP14 and immune cell infiltration was investigated using the Cell-type Identification By Estimating Relative Subsets Of RNA Transcripts (CIBERSORT) and Tumor Immune Estimation Resource (TIMER) tools. In addition, the correlation between MMP14 expression and immune gene markers was analyzed by TIMER and GEPIA.ResultsMMP14 expression positively correlated with favorable progression-free survival (PFS; GSE98588, P = 0.02) and overall survival (OS; GSE98588, P = 0.003; GSE10846, P = 5.517e-05; and GSE4475, P = 9.85e-04). Moreover, MMP14 expression was higher in DLBCL tumors than in normal tissues. Regarding clinical characteristics, high MMP14 expression was found to be correlated with race. MMP14 expression was also correlated with immune cell infiltration and had a remarkable correlation with various immune marker sets. It was found that M0 macrophages were the immune cells most related to survival, decreasing with the increase in Ann Arbor clinical stage. The results especially showed that MMP14 was a prognostic biomarker and related to the macrophages M0.ConclusionThe results suggest that MMP14 is a novel prognostic molecular marker for DLBCL and is related to the immune cell infiltration, especially related to the macrophages M0. Our study provides insights for understanding the potential roles of MMP14 in tumor immunology and its suitability as a prognosis biomarker in DLBCL.

背景：金属蛋白酶14（MMP14）在调节T细胞功能方面扮演着重要角色。然而，MMP14的表达与弥漫大B细胞淋巴瘤（DLBCL）的预后以及免疫细胞浸润之间的关系尚不明确。方法：本研究通过分析来自三个基因表达综合数据库（GEO）数据集（GSE98588、GSE10846和GSE4475）的数据，探讨了MMP14对临床预后的影响。MMP14的表达分析采用基因表达分析互动分析（GEPIA）进行。通过细胞类型识别通过估计RNA转录本的相对亚群（CIBERSORT）和肿瘤免疫估计资源（TIMER）工具，研究了MMP14与免疫细胞浸润的相关性。此外， TIMER和GEPIA工具还用于分析MMP14表达与免疫基因标记物之间的相关性。结果：MMP14的表达与无病进展生存期（PFS；GSE98588，P = 0.02）和总生存期（OS；GSE98588，P = 0.003；GSE10846，P = 5.517e-05；以及GSE4475，P = 9.85e-04）呈正相关。此外，与正常组织相比，DLBCL肿瘤中MMP14的表达更高。在临床特征方面，高MMP14表达与种族相关。MMP14的表达还与免疫细胞浸润相关，并与多种免疫标记物集合具有显著的关联性。研究发现，M0巨噬细胞与生存最为相关，且随着Ann Arbor临床分期的增加而减少。研究结果特别显示，MMP14是一个预后生物标志物，并与巨噬细胞M0相关。结论：研究结果提示，MMP14是DLBCL的一种新型预后分子标志物，与免疫细胞浸润相关，尤其是与巨噬细胞M0相关。本研究为理解MMP14在肿瘤免疫学中的潜在作用及其作为DLBCL预后生物标志物的适用性提供了见解。